Request for Covid-19 Impact Assessment of this Report
Sales, means the sales volume of Antidote
Revenue, means the sales value of Antidote
This report studies sales (consumption) of Antidote in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering
Boehringer Ingelheim Pharmaceuticals
AstraZeneca
Novartis International
Eli Lilly and Company
Market Segment by States, covering
California
Texas
New York
Florida
Illinois
Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into
Chemical Antidotes
Physical Antidotes
Pharmacological Antidotes
Split by applications, this report focuses on sales, market share and growth rate of Antidote in each application, can be divided into
Application 1
Application 2
United States Antidote Market Report 2017
1 Antidote Overview
1.1 Product Overview and Scope of Antidote
1.2 Classification of Antidote
1.2.1 Chemical Antidotes
1.2.2 Physical Antidotes
1.2.3 Pharmacological Antidotes
1.3 Application of Antidote
1.3.1 Application 1
1.3.2 Application 2
1.4 United States Market Size Sales (Volume) and Revenue (Value) of Antidote (2012-2022)
1.4.1 United States Antidote Sales and Growth Rate (2012-2022)
1.4.2 United States Antidote Revenue and Growth Rate (2012-2022)
2 United States Antidote Competition by Manufacturers
2.1 United States Antidote Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Antidote Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Antidote Average Price by Manufactures (2015 and 2016)
2.4 Antidote Market Competitive Situation and Trends
2.4.1 Antidote Market Concentration Rate
2.4.2 Antidote Market Share of Top 3 and Top 5 Manufacturers
2.4.3 Mergers & Acquisitions, Expansion
3 United States Antidote Sales (Volume) and Revenue (Value) by States (2012-2017)
3.1 United States Antidote Sales and Market Share by States (2012-2017)
3.2 United States Antidote Revenue and Market Share by States (2012-2017)
3.3 United States Antidote Price by States (2012-2017)
4 United States Antidote Sales (Volume) and Revenue (Value) by Type (2012-2017)
4.1 United States Antidote Sales and Market Share by Type (2012-2017)
4.2 United States Antidote Revenue and Market Share by Type (2012-2017)
4.3 United States Antidote Price by Type (2012-2017)
4.4 United States Antidote Sales Growth Rate by Type (2012-2017)
5 United States Antidote Sales (Volume) by Application (2012-2017)
5.1 United States Antidote Sales and Market Share by Application (2012-2017)
5.2 United States Antidote Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities
6 United States Antidote Manufacturers Profiles/Analysis
6.1 Boehringer Ingelheim Pharmaceuticals
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Antidote Product Type, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Boehringer Ingelheim Pharmaceuticals Antidote Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 AstraZeneca
6.2.2 Antidote Product Type, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 AstraZeneca Antidote Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Novartis International
6.3.2 Antidote Product Type, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Novartis International Antidote Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Eli Lilly and Company
6.4.2 Antidote Product Type, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Eli Lilly and Company Antidote Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
7 Antidote Manufacturing Cost Analysis
7.1 Antidote Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Antidote
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Antidote Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Antidote Major Manufacturers in 2015
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 United States Antidote Market Forecast (2017-2022)
11.1 United States Antidote Sales, Revenue Forecast (2017-2022)
11.2 United States Antidote Sales Forecast by Type (2017-2022)
11.3 United States Antidote Sales Forecast by Application (2017-2022)
11.4 Antidote Price Forecast (2017-2022)
12 Research Findings and Conclusion
13 Appendix
Methodology
Analyst Introduction
Data Source
Figure Picture of Antidote
Table Classification of Antidote
Figure United States Sales Market Share of Antidote by Type in 2015
Figure Chemical Antidotes Picture
Figure Physical Antidotes Picture
Figure Pharmacological Antidotes Picture
Table Application of Antidote
Figure United States Sales Market Share of Antidote by Application in 2015
Figure United States Antidote Sales and Growth Rate (2012-2022)
Figure United States Antidote Revenue and Growth Rate (2012-2022)
Table United States Antidote Sales of Key Manufacturers (2015 and 2016)
Table United States Antidote Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Antidote Sales Share by Manufacturers
Figure 2016 Antidote Sales Share by Manufacturers
Table United States Antidote Revenue by Manufacturers (2015 and 2016)
Table United States Antidote Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Antidote Revenue Share by Manufacturers
Table 2016 United States Antidote Revenue Share by Manufacturers
Table United States Market Antidote Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Antidote Average Price of Key Manufacturers in 2015
Figure Antidote Market Share of Top 3 Manufacturers
Figure Antidote Market Share of Top 5 Manufacturers
Table United States Antidote Sales by States (2012-2017)
Table United States Antidote Sales Share by States (2012-2017)
Figure United States Antidote Sales Market Share by States in 2015
Table United States Antidote Revenue and Market Share by States (2012-2017)
Table United States Antidote Revenue Share by States (2012-2017)
Figure Revenue Market Share of Antidote by States (2012-2017)
Table United States Antidote Price by States (2012-2017)
Table United States Antidote Sales by Type (2012-2017)
Table United States Antidote Sales Share by Type (2012-2017)
Figure United States Antidote Sales Market Share by Type in 2015
Table United States Antidote Revenue and Market Share by Type (2012-2017)
Table United States Antidote Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Antidote by Type (2012-2017)
Table United States Antidote Price by Type (2012-2017)
Figure United States Antidote Sales Growth Rate by Type (2012-2017)
Table United States Antidote Sales by Application (2012-2017)
Table United States Antidote Sales Market Share by Application (2012-2017)
Figure United States Antidote Sales Market Share by Application in 2015
Table United States Antidote Sales Growth Rate by Application (2012-2017)
Figure United States Antidote Sales Growth Rate by Application (2012-2017)
Table Boehringer Ingelheim Pharmaceuticals Basic Information List
Table Boehringer Ingelheim Pharmaceuticals Antidote Sales, Revenue, Price and Gross Margin (2012-2017)
Figure Boehringer Ingelheim Pharmaceuticals Antidote Sales Market Share (2012-2017)
Table AstraZeneca Basic Information List
Table AstraZeneca Antidote Sales, Revenue, Price and Gross Margin (2012-2017)
Table AstraZeneca Antidote Sales Market Share (2012-2017)
Table Novartis International Basic Information List
Table Novartis International Antidote Sales, Revenue, Price and Gross Margin (2012-2017)
Table Novartis International Antidote Sales Market Share (2012-2017)
Table Eli Lilly and Company Basic Information List
Table Eli Lilly and Company Antidote Sales, Revenue, Price and Gross Margin (2012-2017)
Table Eli Lilly and Company Antidote Sales Market Share (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Antidote
Figure Manufacturing Process Analysis of Antidote
Figure Antidote Industrial Chain Analysis
Table Raw Materials Sources of Antidote Major Manufacturers in 2015
Table Major Buyers of Antidote
Table Distributors/Traders List
Figure United States Antidote Production and Growth Rate Forecast (2017-2022)
Figure United States Antidote Revenue and Growth Rate Forecast (2017-2022)
Table United States Antidote Production Forecast by Type (2017-2022)
Table United States Antidote Consumption Forecast by Application (2017-2022)
Table United States Antidote Sales Forecast by States (2017-2022)
Table United States Antidote Sales Share Forecast by States (2017-2022)
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...